Company Overview

IQVIA Holdings Inc. is a leading global provider of advanced analytics, clinical research services, and technology solutions for the life sciences and healthcare industries. Operating across the Americas, Europe, Africa, and the Asia-Pacific regions, the company offers critical insights and intelligence that help clients navigate complex healthcare ecosystems. IQVIA was formed in 2016 through the merger of Quintiles, a renowned global contract research organization (CRO), and IMS Health, a leader in healthcare data and analytics. This integration created a powerful entity capable of addressing a broad spectrum of industry needs.

Business Operations and Segment Performance

IQVIA's operations are structured across three primary segments: Technology & Analytics Solutions (TAS), Research & Development Solutions (R&DS), and Contract Sales & Medical Solutions (CSMS).

- Technology & Analytics Solutions (TAS): This segment comprises approximately 40% of the company's 2024 revenues. It focuses on health information technology, providing access to a vast repository of over 1.2 billion unique, non-identified patient records globally. TAS offers cloud-based customer relationship management (CRM) application software and advanced analytics services. It also delivers country-level performance metrics on pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across various channels. This segment supports clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, by providing data and analytics capabilities for clinical trials, including virtual trial solutions.

- Research & Development Solutions (R&DS): Accounting for about 55% of 2024 revenues, R&DS functions as a leading contract research organization (CRO). It handles all aspects of clinical trials, from project management and clinical monitoring to strategic planning and design services. The segment offers patient and site-centric solutions, as well as specialized laboratory services including central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker testing. R&DS primarily focuses on providing outsourced clinical trial management, particularly for late-stage trials, for pharmaceutical, medical device, and diagnostic firms.

- Contract Sales & Medical Solutions (CSMS): Representing roughly 5% of 2024 revenues, this segment delivers healthcare provider and patient engagement services, along with scientific strategy and medical affairs support.

Financial Performance

For the fourth quarter of 2024, IQVIA reported revenue of \$3,958 million and GAAP Net Income of \$437 million. For the full year 2024, total revenue reached \$15,405 million, with GAAP Net Income of \$1,373 million. Adjusted EBITDA stood at \$996 million for Q4 2024 and \$3,684 million for the full year 2024.

Key Segment Performance Highlights (Recent Periods):

- Technology & Analytics Solutions (TAS): Revenue of \$1,531 million, showing a 2.1% growth on a reported basis and 1.3% at constant currency.

- Research & Development Solutions (R&DS): Revenue of \$2,151 million, with a 4.5% growth on a reported basis and 3.7% at constant currency.

- R&DS Contracted Backlog: As of December 31, 2023, the R&DS contracted backlog (including reimbursed expenses) was \$29.7 billion, marking a 9.2% year-over-year increase and 8.8% growth at constant currency.

Market Presence and Capabilities

With a global workforce of approximately 87,000 employees, IQVIA operates in over 100 countries. The company serves a diverse client base including pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies.

Technology Innovation

IQVIA leverages its deep expertise in Artificial Intelligence (AI) to address the specific needs of the healthcare sector, developing what it terms "Healthcare-grade AI." The IQVIA Human Data Science Cloud is a core capability designed to facilitate healthcare-grade analytics, provide robust tools, and enable data management solutions for delivering global data at scale.

IQVIA Connected Intelligence™ is an integrated offering that brings together pertinent data, specialized expertise, AI capabilities, advanced analytics, and cutting-edge technology. This comprehensive approach helps clients identify unique needs and discover new opportunities for success.

Core Mission and Vision

IQVIA is dedicated to driving and accelerating change within the healthcare industry. Its primary goal is to generate real, actionable insights that modernize the development and market introduction of new drugs. The company strives to empower its customers with a deeper understanding of complex data, thereby elevating value and improving patient outcomes.

IQVIA's overarching vision is to power smarter healthcare for everyone, everywhere. This is achieved by:

- Speeding up drug development processes.

- Ensuring the quality and safety of pharmaceutical products.

- Enhancing commercial effectiveness for life sciences companies.

- Facilitating the delivery of the right treatments to patients.

- Improving access to and delivery of healthcare services.

- Ultimately, driving better health outcomes for populations worldwide.

IQVIA Holdings Inc. positions itself as an indispensable partner to the life sciences industry, combining extensive data resources, sophisticated analytics, and profound domain expertise to accelerate healthcare innovation and enhance patient well-being on a global scale.